Video

Dr. Edward S. Kim on his "Wish List" for the Future of Immunotherapy in NSCLC

Author(s):

Edward S. Kim, MD

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses immunotherapy in non-small cell lung cancer (NSCLC).

The impact of immunotherapy in NSCLC is unprecedented, said Kim. There are now second-line immunotherapy options with two different single-agents. In the next year, he would like to see expanded indications, most notably in the frontline setting. There are multiple studies being done that are combining immunotherapies with chemotherapy and with biologic therapy.

He is hopeful that there will be multiple approved combinations in 2017 as well as an effective biomarker to determine which patients will most benefit from immunotherapies.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
FDA
January 10th 2025

Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

HCC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 9th 2025

FDA Grants Orphan Drug Designation to Amezalpat for Advanced HCC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Toni Choueiri, MD
January 8th 2025

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC

Sheela Rao, MBBS, MD, FRCP
January 7th 2025

Retifanlimab Emerges as Potential New SOC in Advanced SCAC